Jump to Navigation

In December 2001, the FDA notified Bristol-Meyers Squibb that it must include a black-box (the most serious) warning on its antidepressant product Serzone due to reports of life-threatening hepatic liver failure. On January 9, 2002, Bristol-Meyers Squibb issued a manufacturer's warning to health care providers. The use of Serzone increased the likelihood of developing liver failure 3-4 times the normal likelihood faced by individuals who have NOT taken this drug.

Symptoms of a liver reaction to this antidepressant include jaundice, anorexia, gastrointestinal complaints, and malaise. The most serious reactions to Serzone were convulsions, including grand mal seizures, liver necrosis and liver failure leading to liver transplant and/or death. Physicians were advised to notify their patients to be aware of any side effects similar to those described and the potential for developing liver complications. If you have had any of the side effects associated with liver complications resulting from the use of Serzone, please obtain a Free Consultation by submitting our online form, or by calling 866-273-1941.

OFFICE LOCATION: 707 Grant Street, Suite 2500 | Pittsburgh, PA 15219 | Phone: 866-273-1941 | Fax: 412-281-4229 | Email Us | Get Directions